finanzen.net
24.04.2019 10:34
Bewerten
(0)

Immunovia Interim Report, January-March 2019

DRUCKEN

STOCKHOLM, April 24, 2019 /PRNewswire/ -- During the first quarter of 2019, we remained focused on our product launch strategy and continued to create value, as we reached several key objectives and took several steps towards the commercialization of IMMray™ PanCan-d, our diagnostic test for early detection of pancreatic cancer.

Another key objective that we reached in the first quarter was the addition of new participants to our PanFAM-1 study, a multicenter prospective validation study for early diagnosis of people with a high risk of hereditary pancreatic cancer. In Q1 2019 we added two additional centers, one in Sweden and one in Spain. Umeå University Hospital in Sweden and Catalan Institute of Oncology (ICO Hospitalet) – Bellvitge Biomedical Research Institute (IDIBELL) in Barcelona are now part of PanFAM-1 study.

We also took an extremely important step towards on the optimization of the algorithm during Q1. We announced in March that using blood samples that are as fresh as possible, i.e. stored for less than 24 months, increases the test performance and provides optimal results. We were able to attain the relevant samples through our large and growing network of clinical Key Opinion Leaders (KOL). It is imperative to note that we needed samples that best mirror the blood samples that will be used with our final product, finding these fresh samples and gaining access to them is quite difficult and takes time.

With the appointment of Julie Silber as Senior Investor Relations Director early this year we actualized a strategic objective in strengthening the IR role and our shareholder communication capabilities at Immunovia.

We continued to work intensely during the first quarter of 2019 on the preparations for our sales launch targeted for the beginning of 2020.

Excerpt from the CEO Mats Grahn's comment on the report.

Key Indicators

 

 

Key Indicators (SEK thousand unless otherwise stated)

 

Jan-Mar 2019

 

Jan-Mar 2018

 

Full year 2018

 

 

Full year 2017

 

Net Sales

 

66

 

112

 

333

 

149

 

 

Operating earnings

 

-27,197

 

-17,377

 

-87,708

 

-45,520

 

 

Earnings before tax

 

-26,381

 

-17,326

 

-86,531

 

-45,323

 

 

Net earnings

 

-26,384

 

-17,326

 

-86,536

 

-45,232

 

 

Earnings per share before and after dilution (SEK/share)

 

-1.35

 

-1.00

 

-4.67

 

-2.67

 

 

Equity ratio, %

 

89

 

94

 

97

 

94

 

 

No. of shares at the end of the period

 

19,531,353

 

17,318,059

 

19,531,353

 

17,318,059

 

 

This financial statement has been produced in accordance with IFRS for the Immunovia Group, which comprises Immunovia AB and the wholly-owned subsidiaries Immunovia Incentive AB, Immunovia Inc. and Immunovia GmbH.

Outlook
Immunovia is focused on fundamentally transforming diagnosis of complex forms of cancer and autoimmune diseases. The antibody-based platform, IMMray™, is the result of 15 years of research at CREATE Health – the Center for Translational Cancer Research at Lund University, Sweden. IMMray™ is a technology platform for the development of diagnostic tests and the company's primary test, IMMray™ PanCan–d, is the first test in the world for early diagnosis of pancreatic cancer.

The Company reiterates it's financial targets in accordance with what has previously been disclosed. The company anticipates the first revenues from self pay sales in early 2020.The following financial targets have been established:

  • Immunovia's target is to achieve turnover of SEK 250-300 million by 2022 based on self-pay for IMMray™ PanCan–d.
  • Immunovia's target is to achieve total turnover, including payment via self-pay and cost remuneration from insurance systems, of SEK 800-1,000 million by 2024.

Immunovia invites to a teleconference (in English) for investors, analysts and media on Monday April 29, at 3:00 – 4:00 p.m. CET

Mats Grahn, CEO will present Immunovia and comment on the interim report for the period January-March 2019, give an update from the Annual General Meeting on April 26, followed by a Q&A session. Please call in a few minutes in advance.

To attend, please dial-in at one of the numbers below:

BE: +3226200547 
DK: +4578150110 
FR: +33170750775
DE: +496913803452 
NO: +4723500236 
SE: +46856642695 
CH: +41225675632 
NL: +31207219495 
UK: +443333009274 
US: +18335268383

For questions or interview bookings:
ir@immunovia.com 

There will be an MP3-file available at Immunovia's webpage under Investors/Financial Reports (http://immunovia.com/investors/financial-reports/) for those who want to listen to the telephone conference afterwards. The file will be available within two hours after the conference has ended.

For more information, please contact:
Julie Silber
Director of Investor Relations, Immunovia
Email: julie.silber@immunovia.com
Tel: +46 7 93 486 277

About Immunovia
Immunovia AB was founded in 2007 by investigators from the Department of Immunotechnology at Lund University and CREATE Health, the Center for Translational Cancer Research in Lund, Sweden. Immunovia's strategy is to decipher the wealth of information in blood and translate it into clinically useful tools to diagnose complex diseases such as cancer, earlier and more accurately than previously possible. Immunovia´s core technology platform, IMMray™, is based on antibody biomarker microarray analysis. The company is now performing clinical validation studies for the commercialization of IMMray™ PanCan-d that could be the first blood based test for early diagnosis of pancreatic cancer. In the beginning of 2016, the company started a program focused on autoimmune diseases diagnosis, prognosis and therapy monitoring. (Source: www.immunovia.com)

This information is information that Immunovia AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above.

Immunovia's shares (IMMNOV) are listed on Nasdaq Stockholm. For more information, please visit www.immunovia.com.

This information was brought to you by Cision http://news.cision.com

https://news.cision.com/immunovia-ab/r/immunovia-interim-report--january-march-2019,c2795278

The following files are available for download:

https://mb.cision.com/Main/13121/2795278/1030635.pdf

Press Release

 

Nachrichten zu Immunovia AB

  • Relevant
  • Alle
  • vom Unternehmen
  • Peer Group
  • ?

Keine Nachrichten im Zeitraum eines Jahres in dieser Kategorie verfügbar.

Eventuell finden Sie Nachrichten, die älter als ein Jahr sind, im Archiv

Um Ihnen die Übersicht über die große Anzahl an Nachrichten, die jeden Tag für ein Unternehmen erscheinen, etwas zu erleichtern, haben wir den Nachrichtenfeed in folgende Kategorien aufgeteilt:

Relevant: Nachrichten von ausgesuchten Quellen, die sich im Speziellen mit diesem Unternehmen befassen

Alle: Alle Nachrichten, die dieses Unternehmen betreffen. Z.B. auch Marktberichte die außerdem auch andere Unternehmen betreffen

vom Unternehmen: Nachrichten und Adhoc-Meldungen, die vom Unternehmen selbst veröffentlicht werden

Peer Group: Nachrichten von Unternehmen, die zur Peer Group gehören

Analysen zu Immunovia AB

  • Alle
  • Buy
  • Hold
  • Sell
  • ?
Keine Analysen gefunden.
mehr Analysen

Meistgelesene Immunovia News

Keine Nachrichten gefunden.
Weitere Immunovia News
Anzeige
Anzeige
Börse Stuttgart Anlegerclub

Die richtige Strategie für die Börsenkrise

Stecken Sie nicht den Sand in den Kopf, sondern kaufen Sie die richtigen Aktien. Erfahren Sie im aktuellen Anlegermagazin mehr über attraktive Qualitätsaktien und zyklische Aktien
Kostenfrei registrieren und lesen!

Immunovia Peer Group News

Keine Nachrichten gefunden.

Heute im Fokus

DAX fällt unter 12.000 Punkte -- ifo-Geschäftsklima stärker als erwartet gesunken -- Deutsche Bank will radikaler umbauen: Aktie mit Rekordtief -- KWS SAAT, Pfeiffer Vacuum, GEA im Fokus

CTS Eventim wächst im ersten Quartal dank Tourneegeschäft. So reagieren japanische Unternehmen auf US-Sanktionen gegen Huawei. Deutsche Wirtschaft wächst im ersten Quartal wieder. Umstrittene Listen mit Monsanto-Kritikern sorgen offenbar für Zoff bei Bayer. FAA: Kein Zeitplan für Startgenehmigung für Boeings 737 Max.

Die 5 beliebtesten Top-Rankings

Das hat sich geändert
Diese Aktien hat George Soros im Depot
Big-Mac-Index
In welchen Ländern kostet der Big Mac wie viel?
Das verdienen Aufsichtsratschefs in DAX-Konzernen
Deutlich unter Vorstandsgehältern
Apps & Social Media: Die wertvollsten Marken der Welt
Welche Marke macht das Rennen?
Die Länder mit den größten Goldreserven 2019
Wer lagert das meiste Gold?
mehr Top Rankings

Umfrage

Die rechtspopulistische FPÖ in Österreich hat für einen Skandal gesorgt. Wie glauben Sie wird sich das auf die Europawahlen auswirken?

Online Brokerage über finanzen.net

finanzen.net Brokerage
Handeln Sie für nur 5 Euro Orderprovision* pro Trade aus der Informationswelt von finanzen.net!

ETF-Sparplan

Oskar ist der einfache und intelligente ETF-Sparplan. Er übernimmt die ETF-Auswahl, ist steuersmart, transparent und kostengünstig.
Zur klassischen Ansicht wechseln
Kontakt - Impressum - Werben - Pressemehr anzeigen
Top News
Beliebte Suchen
DAX 30
Öl
Euro US-Dollar
Bitcoin
Goldpreis
Meistgesucht
Wirecard AG747206
Daimler AG710000
Deutsche Bank AG514000
TeslaA1CX3T
CommerzbankCBK100
NEL ASAA0B733
Amazon906866
BayerBAY001
Apple Inc.865985
BASFBASF11
Huawei TechnologiesHWEI11
Ballard Power Inc.A0RENB
Lufthansa AG823212
Infineon AG623100
Deutsche Telekom AG555750